1. Hanauer SB, Present DH: The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Dis 2003, 3:81–92.
2. Sutherland L, MacDonald JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003(3):CD000543. This Cochrane Database review compares the various 5-ASA preparations and sulfasalazine and confirms the efficacy of 5-ASA therapy in the induction of remission in UC.
3. Kane SV, Bjorkman DJ: The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord 2003, 3:210–218.
4. Green JR, Lobo AJ, Holdsworth CD, et al.: Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998, 114:15–22. The first randomized, controlled trial comparing the efficacy of different mesalamine doses in the treatment of mild to moderate UC.
5. Levine DS, Riff DS, Pruitt R, et al.: A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002, 97:1398–1407.